The findings depicted in Fig. 2a, b and Extended Data Fig. 1b, c indicated that the downregulation of NLRP4 in both BRCA-wild-type and BRCA-mutant pancreatic cancer cells heightened their susceptibility to olaparib. The gene discussed is NLRP4; the disease is familial pancreatic carcinoma.